Makers of brand-name drugs can be sued for a longstanding practice of paying competitors to postpone the release of cheaper generic treatments, the U.S. Supreme Court ruled in a 5-3 decision. According to the Federal Trade Com- mission, there were 40 pay-for-delay agreements last year, costing drug consumers an additional $3.5 billion. The industry's trade group said the ruling would dent re- search.
展开▼
